Estrogen receptor (ER), progesterone receptor (PR), and human epithelial growth factor receptor 2 (HER2) are recognized as common clinical tumor markers for tumor growth and progression and as indicators of determining appropriate therapy for patients with breast cancer [3]. This evidence concerns the gene PGR and breast carcinoma.